Cyril Konto

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 1.3K citations

Medicine, Oncology, Immunotherapy +15

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Célèste Lebbé, Jeffrey S. Weber, Michele Maio et al. · Annals of Oncology · 2014 · 142 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Reuben Benjamin, Charlotte Graham, Deborah Yallop et al. · Blood · 2018 · 87 citations

Medicine, Hematology, Oncology +17

Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

Alexander Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · Journal of Clinical Oncology · 2014 · 71 citations

Medicine, Immunology, Oncology +17

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

Sattva S. Neelapu, Javier Muñoz, Frederick L. Locke et al. · Journal of Clinical Oncology · 2020 · 46 citations

Life Sciences, Hematology, Immunology +17